2. Membrane Transporter/Ion Channel
  3. BCRP
  4. P-gp/BCRP-IN-1

P-gp/BCRP-IN-1 (compound 19) is a potential, relatively safe, orally active and efficient efflux transporter (P-gp and BCRP) inhibitor. P-gp/BCRP-IN-1 exerts resistance reversal by inhibiting the efflux function of P-gp and BCRP. P-gp/BCRP-IN-1 can overcome the resistance and improve the oral bioavailability of PTX (Paclitaxel).

For research use only. We do not sell to patients.

P-gp/BCRP-IN-1 Chemical Structure

P-gp/BCRP-IN-1 Chemical Structure

CAS No. : 2764596-06-5

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

P-gp/BCRP-IN-1 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

P-gp/BCRP-IN-1 (compound 19) is a potential, relatively safe, orally active and efficient efflux transporter (P-gp and BCRP) inhibitor. P-gp/BCRP-IN-1 exerts resistance reversal by inhibiting the efflux function of P-gp and BCRP. P-gp/BCRP-IN-1 can overcome the resistance and improve the oral bioavailability of PTX (Paclitaxel)[1].

IC50 & Target

P-gp

 

In Vitro

P-gp/BCRP-IN-1 (compound 19) (0-200 μM, 48 h) has a weak anti-proliferative activity against A549 cells, and shows low cytotoxicity to the K562 , K562/A02, MDCK-II, MDCK-II-BCRP cells[1].
P-gp/BCRP-IN-1 (48 h) exhibits the great reversal effect of resistance to both ADM (Adriamycin) and MX (Mitoxantrone) in K562/A02 cells and MDCK-II-BCRP cells, and increases the reversal activity of ADM (0-5 μM) and MX (0-20 μM) in a concentration-dependent manner[1].
P-gp/BCRP-IN-1 (0-5 μM, 4 h) increases drug accumulation and prevents efflux of P-gp and BCRP[1].
P-gp/BCRP-IN-1 (0-5 μM, 48 h) dose not affect the expression of P-gp as well as BCRP protein[1].
P-gp/BCRP-IN-1 (0-200 μM, 4 h) decreases the viability of Caco-2 cells, inhibits the intestinal P-gp-mediated efflux of PTX and increases its concentration in the intestinal cells, can enhance the absorption and bioavailability[1].
P-gp/BCRP-IN-1 prevents intracellular accumulation of anti-neoplastic drugs by impairing the function of P-gp and BCRP[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

P-gp/BCRP-IN-1 Related Antibodies

Cell Proliferation Assay

Cell Line: A549 cells, chemo-sensitive cell lines (K562, MDCK-II), chemo-resistant cell lines (K562/A02, MDCK-II-BCRP)[1]
Concentration: 200, 100, 50, 25, 12.5, 6.25, 3.125, 1.56 and 0 μM
Incubation Time: 24, 48 h
Result: Had a weak anti-proliferative activity against A549 cells, with an IC50 of 46.28 μM, and showed low cytotoxicity to the K562 , K562/A02, MDCK-II, MDCK-II-BCRP cells, with IC50 values of 72.81, 43.29, 87.69, 81.22 μM, respectively.

Cell Viability Assay

Cell Line: K562/A02 cells and MDCK-II-BCRP cells[1]
Concentration: 5 μM
Incubation Time: 48 h
Result: Increased the reversal activity of ADM (0-5 μM) and MX (0-20 μM) in a concentration-dependent manner, exhibited the great reversal effect of resistance to both ADM and MX in K562/A02 cells and MDCK-II-BCRP cells, with IC50 values (at 5 μM) of 2.41 and 18.43 μM, RF (reversal fold, at 5 μM) of 40.51 and 37.40, and EC50of 65.31 and 98.22 nM, respectively.

Western Blot Analysis

Cell Line: K562/A02 cells and MDCK-II-BCRP cells, K562 and MDCK-II cells.[1]
Concentration: 0, 0.5, 1, 5 μM
Incubation Time: 48 h
Result: Did not affect the expression of P-gp as well as BCRP protein, exerted resistance reversal without affecting the expression of P-gp as well as BCRP protein, but probably by inhibiting the efflux function of P-gp and BCRP.

Cell Viability Assay

Cell Line: Caco-2 cells[1]
Concentration: 1.25, 5, 10, 20, 30, 50, 100, 200 μM
Incubation Time: 4 h
Result: Decreased the viability of Caco-2 cells to less than 20% at concentrations of 30 and 50 μM respectively, significantly decreased the Papp (apparent permeability coefficient) value, inhibited the intestinal P-gp-mediated efflux of PTX and increased its concentration in the intestinal cells, which could eventually enhance the absorption and bioavailability of the orally administered drug.
In Vivo

P-gp/BCRP-IN-1 (compound 19) (Male SD rats; 5 mg/kg PTX (IV), 20 mg/kg PTX (PO), 20 mg/kg PTX and 10 mg/kg compound 19 (PO); once) increases the bioavailability of PTX when PTX is given orally[1].
Pharmacokinetic Parameters of P-gp/BCRP-IN-1 in male SD rats[1].

PTX (5 mg/kg) PTX (20 mg/kg) PTX (20 mg/kg) with 19 (10 mg/kg)
Routemax (h) IV PO PO
AUC0-t (ng*h/mL) 1734.95 ± 244.28 610.89 ± 45.62 3131.51 ± 63.17
Cmax (ng/mL) 925.86 ± 31.39 112.09 ± 25.46 652.31 ± 41.93
Tmax (h) 0.44 ± 0.05 2.00 ± 0.03 2.51 ± 0.19
T1/2 (h) 0.12 ± 0.03 1.35 ± 0.05 1.68 ± 0.15
Vd/F (L) 5.06 ± 0.09 67.38 ± 12.54 16.04 ± 0.08
CL/F (L/h) 2.88 ± 0.14 32.74 ± 5.42 6.18 ± 0.36
F (%) 100 8.80 45.1

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male SD rats (n = 15, three groups)[1]
Dosage: 5 mg/kg PTX (IV); 20 mg/kg PTX (PO); 20 mg/kg PTX with 10 mg/kg compound 19 (PO)
Administration: IV, PO, once (Pharmacokinetic Analysis)
Result: Increased the bioavailability of PTX when PTX was given orally.
Molecular Weight

488.97

Formula

C27H25ClN4O3
CAS No.
SMILES

O=C(C1=NN(C(C2=CC=CC=C21)=O)C3=CC=C(C=C3)Cl)NC4=CC=C(C=C4)CCN5CCOCC5
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

P-gp/BCRP-IN-1 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

P-gp/BCRP-IN-12764596-06-5BCRPBreast cancer resistance proteinABCG2Efflux transporterMultidrug resistance (MDR)Paclitaxel (PTX)Oral bioavailabilityLow cytotoxicityOrally activeInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
P-gp/BCRP-IN-1
Cat. No.:
HY-144393
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.